Researcher

Scientia Professor Gregory John Dore

My Expertise

Gastroenterology and Hepatology - Infectious Diseases (Hepatitis A/B).

Fields of Research (FoR)

Infectious Diseases, Gastroenterology and Hepatology

Biography

Professor Dore is Head, Viral Hepatitis Clinical Research Program, Kirby Institute, UNSW Sydney, and Infectious Diseases Physician, St Vincent’s Hospital, Sydney, Australia. He has been involved in viral hepatitis and HIV epidemiological and clinical research, clinical care and public health policy for 25 years. He has developed extensive national and international collaborations, and is internationally recognized in the areas of HCV natural...view more

Professor Dore is Head, Viral Hepatitis Clinical Research Program, Kirby Institute, UNSW Sydney, and Infectious Diseases Physician, St Vincent’s Hospital, Sydney, Australia. He has been involved in viral hepatitis and HIV epidemiological and clinical research, clinical care and public health policy for 25 years. He has developed extensive national and international collaborations, and is internationally recognized in the areas of HCV natural history and epidemiology, therapeutic strategies for acute and chronic HCV infection, particularly among people who inject drugs, and HCV elimination strategies.

He holds large-scale ongoing public sector research funding from U.S. National Institutes for Health and Australian National Health and Medical Research Council (NHMRC).

Professor Dore has been President of the Australasian Society for HIV Viral Hepatitis and Sexual Health Medicine (ASHM), a member of NHMRC Council, and is a NHMRC Practitioner Fellow.

Professor Dore established the St Vincent’s Hospital viral hepatitis service in 1999, and has led its development into one of the leading national and international hepatitis C treatment services, with a particular focus on marginalised populations including people who inject drugs and homeless persons.

My Grants

Major Category 1 Grants

NHMRC: Practitioner Fellowships (2012-2016: $523K; renewed for 2017-2021: $569K).
NHMRC Program Grants as CI (2014-2018: $5.4M; CIA 2019-2023: $9.0M).
NHMRC Partnership Grants as CI (2014-2019: Surveillance and Treatment of Prisoners with hepatitis C (SToP-C), $1,495K; 2016-2020: Enhancing hepatitis C virus among injecting drug users in the opiate pharmacotherapy setting, $1,490K).
NIH R01 Grants as CI (2015-2020: A randomised study of interferon-free treatment for recently acquired hepatitis C in people who inject drugs and people with HIV coinfection (REACT study), $US 3,700K; 2011-2016: International Collaborative of prospective studies of HIV and Hepatitis in IDU, $2,289K).